Compare HP Inc (HPQ) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs 10X Genomics Inc — how do they compare? HP Inc trades at $28.46 (market cap $26.59B), while 10X Genomics Inc trades at $58.29 (market cap $7.61B). The key difference: HP Inc is far larger — about 3.5× 10X Genomics Inc's market cap, and HP Inc pays a 4.13% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| HPQ | TXG | |
|---|---|---|
Market Cap | $26.59B | $7.61B |
Sector | Technology | Health |
52-Week High | $30.05 | $58.57 |
52-Week Low | $18.20 | $11.34 |
Enterprise Value | $33.75B | $7.14B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $29.80, down 0.83% on the day, with a bullish technical signal supported by moving averages and positive earnings beats in recent quarters. The company reported Q2 2026 revenue of $14.4B and EPS of $0.86, exceeding expectations, driven by premium product mix and AI-driven efficiencies. Valuation metrics show a P/E of 10.77 and P/S of 0.48, indicating potential undervaluation relative to historical averages.
The outlook remains positive with continued earnings momentum and a 2026 revenue forecast of $57.4B, though risks include PC market volatility and competitive pressures. Analyst consensus is mixed with 29% buy ratings, but technical support at $29 suggests near-term stability. The dividend yield of approximately 4% provides income appeal amid growth initiatives.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
